Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients

Uchiyama, Kazuki; Saito, Yoshitaka; Takekuma, Yoh et al.

Journal of oncology pharmacy practice, 2020, 28(1), 31-38

Permalink : https://hdl.handle.net/2115/81072

このアイテムのアクセス数:667件（2026-08-19 11:04 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
Kazuki Uchiyama HUSCAP pdf 379 KB 664

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/81072
タイトル
Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients
著者
Uchiyama, Kazuki ; Saito, Yoshitaka ; Takekuma, Yoh ; Sugita, Junichi ; Teshima, Takanori ; Sugawara, Mitsuru
著者名
Uchiyama, Kazuki
e-Rad_Researcher
00835001
著者名
Saito, Yoshitaka
e-Rad_Researcher
00396293
著者名
Takekuma, Yoh
著者名
Sugita, Junichi
e-Rad_Researcher
40284096
著者名
Teshima, Takanori
e-Rad_Researcher
60332467
著者名
Sugawara, Mitsuru
言語
英語
キーワード
Mycophenolate mofetil (MMF)
mycophenolic acid (MPA)
haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
enterohepatic circulation (EHC)
発行日
2020-12-22
出版者
SAGE Publications
収録物名
Journal of oncology pharmacy practice
巻(号)
28(1)
ページ
31-38
抄録
Purpose : Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) prodrug, is used to prevent graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). Although previous studies have reported that enterohepatic circulation (EHC) of MPA, which is usually observed in MMF-treated patients, does not occur in HSCT patients, it is unclear what happens in haploidentical-HSCT (haplo-HSCT) patients, who are using post-transplant cyclophosphamide. This study was conducted to investigate MPA pharmacokinetics in haplo-HSCT patients. Methods : Seventeen haplo-HSCT patients, who received MMF for GVHD prophylaxis, were enrolled in this study. We collected blood samples on days 14 and 28, and plasma MPA concentrations were measured by high-performance liquid chromatography; pharmacokinetic parameters such as area under the curve (AUC), mean residence time (MRT), and apparent oral clearance (CL/F) were measured with moment analysis. We also evaluated EHC as AUC(6-12h)/AUC(0-12h.) Results : There was no significant difference in MPA pharmacokinetic parameters between days 14 and 28. There was also no difference between the pharmacokinetic parameter changes and diarrhea. Additionally, varying plasma MPA concentrations suggested that MPA EHC did not occur. Conclusion : In this study, we revealed the pharmacokinetics of MMF in Japanese haplo-HSCT recipients. Additionally, our study demonstrated that MPA EHC might not occur in Japanese haplo-HSCT recipients.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
Kazuki Uchiyama, Yoshitaka Saito, Yoh Takekuma, Junichi Sugita, Takanori Teshima, Mitsuru Sugawara, Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients, Journal of Oncology Pharmacy Practice (OnlineFirst), Copyright © 2020., DOI:10.1177/1078155220980815.
PISSN
1078-1552
EISSN
1477-092X
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1177/1078155220980815